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Background and objective: The aim of this randomized, single dose, two-period crossover
study with two weeks wash-out period was the demonstration of bioequivalence of two
recombinant human granulocyte colony-stimulating factor (rG-CSF) formulations after
subcutaneous administration of 300 mg comparing their pharmacokinetic (primary end-
points AUC0–24, AUC0–1 and Cmax) and pharmacodynamic (primary endpoints ANC AUC0–72,
ANC AUC0–1 and ANCmax) proﬁles in healthy male subjects.
Materials and methods: A total of 36 (23.0  6.0 years, 76.6  7.2 kg) healthy subjects were
recruited. Using a 1:1 randomization ratio, subjects were randomly assigned to one of two
possible treatment-sequence groups to receive the single dose of test formulation (Gp-02)
and reference product (NeupogenTM) concentrations were measured by enzyme-linked
immunosorbent assay (ELISA) up to 24 h and the Absolute Neutrophil Count (ANC) was
determined using hematology analyzer Coulter STKSTM (Beckman Coulter) up to 72 h after
injection. The geometric mean of primary pharmacokinetic and pharmacodynamic vari-
ables were considered bioequivalent if the 90% conﬁdence intervals (CI) would fall in the
bioequivalence range of 80%–125%.
Results: AUC0–24 (ratio of means 103.4, 90% CI: 95.6–111.9), AUC0–1 (103.4, 90% CI: 95.7–111.7),
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90% CI: 96.5–105.3), and ANCmax (100.2, 90% CI: 95.4–105.1) were determined. Single doses of
test and reference formulations were well tolerated. The incidence of AEs was equally
distributed across treatment groups with the most frequent AEs being headache, fever, and
back pain.
Conclusions: The study results demonstrated the bioequivalence of Gp-02, a new formulation of
ﬁlgrastim, and the reference product NeupogenTM.
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Human granulocyte colony stimulating factor (G-CSF) is a
glycoprotein, which regulates the differentiation of neutro-
phils from progenitor cells and stimulates the release from the
bone marrow and also activates circulating neutrophils.
Endogenous G-CSF is produced mainly by mononuclear cells
and ﬁbroblasts. G-CSF markedly increases neutrophil counts
in peripheral blood, slightly elevates levels of monocytes and
lymphocytes and mobilizes blood progenitor cells (CD34+) into
circulation [1]. Peak levels of neutrophils are reached approxi-
mately 12 h after ﬁlgrastim administration. Absolute neutro-
phil count (ANC) returns to pre-treatment levels around 48–
72 h after cessation of ﬁlgrastim administration. Evaluation of
pharmacokinetics in human subjects indicates that recombi-
nant G-CSF (ﬁlgrastim) is quickly absorbed after subcutaneous
bolus injection and follows ﬁrst order elimination kinetics.
Serum elimination half-life of ﬁlgrastim is approximately
3.5 h, with the clearance rate of approximately 0.6 mL/min/kg
[2].
New recombinant G-CSF (Gp-02) has been developed by the
Sponsor of the study – Sicor Biotech UAB (Teva Group,
Lithuania). The recombinant G-CSF is bacterially synthesized,
i.e., produced in genetically modiﬁed Escherichia coli. It differs
from endogenous G-CSF since it has an N-terminal methionine
residue and is not glycosylated, but the biological activity of
recombinant G-CSF is the same as of endogenous human G-
CSF. The reference product NeupogenTM (Amgen, Thousand
Oaks, USA) was authorized in European Union (EU) more than
two decades ago and is used to reduce the duration of
neutropenia and the incidence of febrile neutropenia, associ-
ated with cytotoxic chemotherapy and also to increase the
number of hematopoietic stem cells in the blood before
collection by leukapheresis for use in hematopoietic stem cell
transplantation.
The physicochemical comparison of two ﬁlgrastim pro-
ducts demonstrated similarity regarding molecular weight,
amino acid sequence, tertiary structure, impurity proﬁle, as
requested by European Medicines Agency (EMA) regulations
for biosimilar medicinal products [3]. Current study was
designed to collect pharmacokinetic and pharmacodynamic
proﬁle of new ﬁlgrastim product in support of biosimilarity.
The primary objective of the study was the demonstration of
bioequivalence of the two ﬁlgrastim formulations after
subcutaneous administration of 300 mg single dose, comparingtheir pharmacokinetic and pharmacodynamic properties in
healthy subjects.
2. Materials and methods
2.1. Subjects
The study protocol and amendments were approved by the
local Ethics Committee and Lithuanian State Medicines
Control Agency (SMCA). The study was conducted in compli-
ance with the Declaration of Helsinki and according to Good
Clinical Practice (GCP). All healthy male volunteers who gave
their written informed consent to participate and corre-
sponded to selection criteria were included in this study.
Volunteers were free to withdraw from the study at any time.
Volunteers were considered healthy if they had no history of any
chronic diseases and no pathological symptoms or signs at the
physical examination and the laboratory test (complete proﬁle of
blood cell counts, routine serum biochemistry, urinalysis,
hepatitis B surface antigen, hepatitis C antibody and human
immunodeﬁciency virus antibodies). The subjects were not
included if they had allergic or idiosyncratic reactions to any
drug, any clinically relevant allergic disease, received treatment
with blood cell colony-stimulating factors, interleukins or
interferons or had general anesthesia or blood donations within
3 months. The subjects were instructed not to take other
medications or alcohol throughout the study and to avoid
strenuous exertion. Withdrawn subjects were not replaced. The
follow-up of withdrawn subjects was carried-out within 14 days
after the last study drug administration or when any clinically
signiﬁcant changes were resolved and when the investigator
deemed that no further investigations were indicated.
2.2. Study design and sample size
This was a randomized, single dose, two-period crossover
study in healthy subjects. There was a two weeks wash-out
period after the ﬁrst treatment period.
The sample size was determined according multiplicative
model [4]. A total of 36 healthy subjects were planned to recruit
ensuring 80% statistical power (a = 0.05) to demonstrate
bioequivalence between test formulation Gp-02 and Neupo-
genTM assuming an intrasubject coefﬁcient of variation (CV) of
21% and a bioequivalence range of 0.80–1.25 for the test (T) and
reference (R) area under curve (AUC) mean ratio.
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Test formulation (Gp-02), containing 300 mg ﬁlgrastim at a ﬁll
volume of 1.0 mL, was manufactured by Sicor Biotech UAB (Teva
Group) as sterile solution in pre-ﬁlled syringes ready for
injection. Reference preparation was the marketed formulation
of NeupogenTM containing 300 mg ﬁlgrastim at a ﬁll volume of
1.0 mL produced by Amgen Inc (Thousand Oaks, CA, USA), as
sterile solution for injection in vials. The Gp-02 formulation had
the same strenght and composition as the reference product,
the marketed medicinal product NeupogenTM.
Each eligible subject received a single dose of 300 mg of
each: test and reference formulations in a randomized
crossover design. Randomization was made using procedure
PLAN of SAS. Using a 1:1 randomization ratio, subjects were
randomly assigned to one of two possible treatment-sequence
groups to receive either T or R drug in Period 1. After a two
weeks wash-out period subjects received the alternative
treatment in Period 2. The exact dose of 300 mg was
administered via the subcutaneous route. The investigational
product was administered to the subjects after overnight
fasting at around 8.00 A.M. in the back of upper arm.
2.4. Study assessments and analytical methods
Blood samples for serum G-CSF concentration determination
were collected by venipuncture into labeled tubes (SST) of 6 mL
volume at the following time points: 0, 20, 40, 60, 90 min, 2, 3, 4,
6, 8, 12, and 24 h after injection. G-CSF concentrations were
measured by a validated quantitative sandwich enzyme-
linked immunosorbent assay (ELISA) method (Quantikine®,
R&D System, Inc) at the qualiﬁed clinical laboratory (Centre for
Communicable Diseases and AIDS, Vilnius, Lithuania). The
LLOQ (Lower Limit of Quantiﬁcation) was 50 pg/mL, the ULOQ
(Upper Limit of Quantiﬁcation) was 1800 pg/mL. Intra-assay CV
was 2.8, 1.7 and 1.1% for 280, 827 and 1696 pg/mL, respectively.
Inter-assay CVs were 4.1, 3.2 and 3.8% for 176, 1094 and
2169 pg/mL, respectively.
Blood samples for Absolute Neutrophil Count (ANC) were
collected by venipuncture at the following time points: 0, 20,
40, 60, 90 min, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40, 48 and 72 h after
injection. The ANC was determined using the differential
automated hematology analyzer Coulter STKSTM (Beckman
Coulter, Inc., Fullerton, CA, USA) at the qualiﬁed clinical
hematology laboratory (Kaunas Clinical Hospital, Kaunas,
Lithuania).
All subjects were analyzed for safety. Standard safety
variables were used in the study: vital signs (blood pressure,
heart rate, body temperature), laboratory controls: hematolo-
gy, biochemistry (potassium, creatinine, uric acid), liver
function tests (aspartate transaminase (ALT), alkaline phos-
phatase (AST)), coagulation tests and urinalysis. The subjects
were routinely followed until 72 h after injection in both
treatment periods. All adverse events (AEs) were followed until
their resolution.
2.5. Statistical analysis
The area under the serum concentration-time curve (AUC)
from 0 to 24 h and the area under the ANC-time curve from 0 to72 h were calculated using the trapezoidal rule using the actual
times of measurements. The time at which peak concentra-
tion/ANC value occurred (Tmax) was determined directly from
the experimental data as the time of maximum concentration/
ANC observed (Cmax) considering the entire curve. The
terminal elimination rate constant (lz) was calculated from
the slope of the semilogarithmic plot of the terminal phase of
the plasma concentration-time curve determined by linear
regression. The elimination half-life (T1/2) was calculated from
the terminal elimination rate constant (lz). Pharmacokinetic
(AUC0–24, AUC0–1, Cmax, Tmax, T1/2, lz) and pharmacodynamic
(ANC AUC0–72, ANC AUC0–1, ANCmax, ANCtmax) variables
were analyzed by non-compartmental model following a
trapezoidal rule [5].
The statistical analysis was performed using SAS System
for Windows, version 9.1.2 (SAS Institute, Inc., Cary, NC, USA).
Descriptive statistics was applied to the data of all randomized
subjects who had received at least one dose of the investiga-
tional product. The data from test and reference products were
tested by parametric and nonparametric approaches. Normal-
ity of distribution was tested with Shapiro-Wilk's test from the
SAS UNIVARIATE procedure. A parametric (normal-theory)
approach was applied for the analysis of log-transformed
parameters (Cmax, AUC0–t and AUC0–1). Non log-transformed
parameters (Tmax, lz and T1/2,) were evaluated by non-
parametric tests. Schuirmann's two one-sided tests and the
90% conﬁdence intervals were determined for the log-
transformed parameters. The pharmacodynamic variables
were treated similarly. Only those subjects who completed
both study periods were included in the bioequivalence
analysis. The formulations were considered bioequivalent
when the difference between the compared primary phar-
macokinetic (AUC0–24, AUC0–1 and Cmax) and primary phar-
macodynamic (ANC AUC0–72, ANC AUC0–1 and ANCmax)
parameters was found statistically insigniﬁcant and the
90% conﬁdence intervals were within the bioequivalence
range of 80%–125% [6,7].
3. Results
3.1. Subjects' demographics and disposition
A total of 36 healthy male Caucasian subjects met all
inclusion/exclusion criteria and were recruited. The age
ranged from 18 to 41 years (23.0  6.0 years, subjects' body
weight was between 59 and 91 kg (76.6  7.2 kg) and height was
between 168 and 195 cm (178.5  28.1 cm). One subject due
to fulﬁllment to exclusion criteria before second study
period (use of restricted medication) discontinued the study
prematurely. Thirty-ﬁve volunteers completed the study and
were considered for pharmacokinetic and pharmacodynamic
evaluation.
3.2. Pharmacokinetics and pharmacodynamics
The mean plasma concentration-time proﬁles of test and
reference ﬁlgrastim formulations after subcutaneous injec-
tion of 300 mg single dose is displayed in Fig. A. Baseline levels
of G-CSF were not detected in any of the subjects. The
Fig. – Mean observed recombinant G-CSF concentration-
time (A) and ANC-time profiles (B) after subcutaneous
administration of 300 mg single dose of filgrastim to
healthy volunteers.
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tions exhibited high similarity. The mean plasma G-CSF
concentrations exhibited its peak after 4 h for both drug
products (range 3.0–6.0 h) (Table 1). Thereafter, the concen-
trations decreased in monophasic manner in both dosage
groups. Table 2 shows the results of statistical comparison of
the primary pharmacokinetic parameters. The conﬁdence
intervals for the primary pharmacokinetic parameters were
within 80%–125% interval. The nonparametric 90% conﬁ-
dence intervals for the pharmacokinetic parameters Tmax, T1/2
and lz were also enclosed in the 20% acceptance range.Table 1 – Pharmacokinetic and pharmacodynamic parameters a
G-CSF to healthy volunteers.
Parameter Test formu
(SD) n = 
AUC0–24, ng  h/mL 168.7 (56
AUC0–1, ng  h/mL 170.5 (56
Cmax, ng/mL 20.3 (6.8
tmax, h 4.6 (1.2
t1/2, h 3.3 (0.4
lz, h
1 0.2 (0.0
ANC AUC0–72, h  109/L 894.7 (17
ANC AUC0–1, h  109/L 1086.83 (1
ANCmax, 10
9/L 25.9 (6.5
ANC tmax, h 11.8 (1.7
Values are mean (standard deviation).
Cmax, peak concentration; AUC0–24, the area under the concentration/
extrapolated to inﬁnity; tmax, time at which Cmax occurred; t1/2, the elimin
value of ANC determined; ANC AUC0–72, the area under the blood ANC/
extrapolated to inﬁnity; ANC tmax, time at which ANCmax occurred.The mean ANC-time proﬁles of test and reference for-
mulations are shown in Fig. B. The ANC-time proﬁles between
the test and the reference formulations in both dosage groups
were virtually superimposable. Initially, a fall in ANC below
baseline was observed at 20 min to 1 h after administration of
both test and reference formulations. Subsequently, ANC
started to increase, passed baseline at around 90 min and
further increased. The maximal ANC values were observed
at around 12 h after administration. The increase in ANC for
all subjects has returned to baseline values after 72 h (Fig. B).
Table 2 shows the results of statistical comparison of the
pharmacodynamic parameters in both treatment groups.
The conﬁdence intervals for the primary pharmacodynamic
parameters were within 80%–125% interval and the nonpara-
metric 90% conﬁdence intervals for the pharmacodynamic
parameter ANC tmax were within the 20% acceptance
range.
3.3. Safety
During the study, 24 subjects reported in total 41 adverse
events (AEs): 14 subjects reported 21 AEs after administration
of test formulation and 17 subjects reported 20 AEs after
administration of reference formulation. The following AEs
were reported most frequently: headache (13 events in 10
subjects), fever (9 events in 9 subjects) and back pain (3 events
in 3 subjects). The most frequent AEs deﬁned as laboratory
abnormalities were: increase in ALT activity (3 events in 3
subjects) and hyperuricemia (2 events in 2 subjects).
Thirty-six AEs were reported as related to investigational
products: 19 AEs after administration of the test and 17 AEs
after the reference formulations. The AEs considered at least
possibly related to the study drugs were (in the order of
decreasing frequency): headache, fever, back pain, increased
ALT, hyperuricemia, sweating, hypertension, increased phos-
phatemia, weakness.
The incidence of different AEs was similarly distributed
across treatment groups.fter subcutaneous administration of 300 mg of recombinant
lation
35
Reference formulation
(SD) n = 35
.6) 161.7 (77.3)
.9) 163.5 (47.5)
) 20.1 (5.7)
) 4.5 (1.0)
) 3.4 (0.5)
3) 0.2 (0.03)
4.6) 889.7 (150.6)
8.9) 1074.7 (164.0)
) 25.5 (5.9)
) 11.8 (1.7)
time curve; AUC0–1, the area under the concentration/time curve
ation half-life; lz, the elimination rate constant; ANCmax, the highest
time curve; ANC AUC0–1, the area under the blood ANC/time curve
Table 2 – Statistical analysis of primary pharmacokinetic and pharmacodynamic parameters after subcutaneous
administration of 300 mg of recombinant G-CSF to healthy volunteers.
Parameter T/R point estimate % (90% CI) Intrasubject CV, %
AUC0–24, ng  h/mL 103.4 (95.6–111.9) 19.73
AUC0–1, ng  h/mL 103.4 (95.7–111.7) 19.20
Cmax, ng/mL 99.6 (89.0–111.4) 28.2
ANC AUC0–72, h  109/L 100.0 (96.6–103.5) 8.57
ANC AUC0–1, h  109/L 100.8 (96.5–105.3) 10.73
ANCmax, 10
9/L 100.2 (95.4–105.1) 11.95
Cmax, peak concentration; AUC0–24, the area under the concentration/time curve; AUC0–1, the area under the concentration/time curve
extrapolated to inﬁnity; ANCmax, the highest value of ANC determined; ANC AUC0–72, the area under the blood ANC/time curve; ANC AUC0–1,
the area under the blood ANC/time curve extrapolated to inﬁnity.
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The standard scientiﬁc approach and regulatory rules for
testing for bioequivalence were applied for this study in order
to assess new biosimilar and reference ﬁlgrastim drugs in
terms of bioavailability and pharmacological activity, by
measuring G-CSF plasma concentration and ANC, which is a
relevant pharmacodynamic biomarker of the efﬁcacy of G-CSF
drug products. Each formulation was administered as a single
dose via the subcutaneous route in a cross-over design in two
periods, separated by a wash-out phase of 14 days. The chosen
design followed guidelines of the European Medicines Agency
(EMA), published at the time of the study, including Guideline
on the investigation of bioavailability and bioequivalence.
There was no statistically signiﬁcant carry-over effect for
pharmacokinetic and pharmacodynamic variables, what can
be considered as an indicator of adequate study design and
conduct. To ensure a reliable estimate of the extent of drug
absorption and of the effect on pharmacodynamic marker
(ANC in this study), a blood sampling period of 3 half-lives was
applied, as recommended by different guidelines. Mean
extrapolated area was below 20% for test and reference
formulations in both treatment groups (more than 80% of
the AUC0–1 and ANC AUC0–1 was covered by the AUC0–24 and
ANC AUC0–72 for test and reference formulations respectively).
This indicates that the blood sampling collection period was
adequate to characterize the pharmacokinetic and pharma-
codynamic properties of the recombinant G-CSF.
In this study the 300 mg dose was chosen for a single-dose
administration. It corresponded to the mean dose of 5 mg per
kg of body weight. This is in compliance with the recommen-
dation that the dose used in the bioequivalence study should
be close to daily doses of the treatment of most therapeutic
indications [8]. The selected doses were similar to the doses
administered in other ﬁlgrastim studies in healthy volunteers
[9–12]. Pharmacokinetic data obtained in this study are in line
with those reported in previous studies, performed with
ﬁlgrastim in healthy volunteers [12–14], as well as with the
newly published data of new biosimilar ﬁlgrastim drugs [6,15].
The increases of ANC in study subjects in both dosage
cohorts were preceded by initial decreases in neutrophils
count over the ﬁrst 20 min after administration of investiga-
tional products. The assumed mechanism responsible for this
initial ANC decrease can be margination of the neutrophils toendothelial cells [16]. The subsequent ANC increase following
the initial decrease in ANC is considered to be caused by the
release of mature neutrophils from the reserve pool of
postmitotic mature myelocytes [17]. Both formulations effec-
tively increased the ANC, the changes of this main pharmaco-
dynamic marker of recombinant G-CSF were almost
superimposable for 2 compared formulations. This could be
explained by identical molecular structure and other physico-
chemical properties of two drugs, as demonstrated by
comparability exercise and the same pharmaceutical formu-
lation. ANC is considered as relevant biomarker for the efﬁcacy
of the product, as it is a diagnostic criterion of acute febrile
neutropenia and also a predictor of the risk of infections in the
patients with chemotherapy-induced neutropenia. Demon-
stration of pharmaceutical efﬁcacy equivalence by ANC proﬁle,
together with pharmacokinetic equivalence and demonstra-
tion of the same well-deﬁned physicochemical properties
should be considered already to be a solid proof of the
biosimilarity of ﬁlgrastim products.
The parameter ANCmax (25.9  109/L) was similar in other
clinical trials. Range of ANCmax was from 21.7 to 36.09  109/L
[10,11,19] [20]. ANC tmax (11.8 h) was not different in other
clinical trials too. Range of ANC tmax was from 7.8 to 13.1 h
[10,11,18,19]. Other study revealed ANC AUC0–1
(1086.83 h  109/L), which was not different from our study
established range – 945–1663 h  109/L [10,11,18,19].
The safety data obtained during this study indicate that
single doses of 300 mg/mL of recombinant G-CSF were well
tolerated. Main drug-related adverse events like headache,
musculoskeletal pain, modiﬁcation of laboratory tests are
corresponding to those published for the originator product
(SPC of NeupogenTM) and of more recently developed other
biosimilar ﬁlgrastim products [9–11,19].
5. Conclusions
The study results demonstrated the bioequivalence of two
formulations Gp-02, a new biosimilar formulation of ﬁlgras-
tim, and the reference product NeupogenTM after administra-
tion of a 300 mg/mL dosage strength with respect to
pharmacokinetic, pharmacodynamic and safety proﬁles. The
observed pharmacokinetic and pharmacodynamic data sup-
port the biosimilarity of the new recombinant G-CSF to the
reference medicinal product NeupogenTM.
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